Preformulation and development of preliminary nanoemulsion carrier for patent protected compound GL-II-73

Jelena Đoković^{1*}, Bojan Marković², Dishary Sharmin³, James M Cook³, Miroslav Savić⁴, Snežana Savić¹



¹University of pharmacy - Faculty of pharmacy, Department of pharmaceutical technology and cosmetology, 11221 Belgrade, Serbia ²University of pharmacy - Faculty of pharmacy, Department of pharmaceutical chemistry, 11221 Belgrade, Serbia

³Department of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, WI, 53201, USA

⁴University of pharmacy - Faculty of pharmacy, Department of pharmacology, 11221 Belgrade, Serbia *presenting author


CONCLUSION

Preliminary studies suggest that nanoemulsions are good potential carriers for GL-II -73, but further research is needed to optimise stability.

INTRODUCTION AND AIMS

Nanopharmaceuticals offer a good way to circumvent some of the difficulties faced by new drug candidates. They can be tailored to adjust their water solubility, half-life, and biodistribution or to control the release of the integrated drug. Due to the excipients used, lipid nanocarriers (liposomes, nanoemulsions (NEs), nanoparticles) were used to improve targeting to the brain (1,2). The investigated compound GL-II-73 is an imidazobenzodiazepine (IBZD) ligand that acts as a positive allosteric modulator at α-GABAA receptors and has been shown to have a combined antidepressant and cognition enhancing effect, making it a promising candidate for further research (3).

The aim of this work is to investigate the physicochemical properties of GL-II -73 to select the best parenteral nanodelivery system for future research and evaluate its parameters.



Solubility of GL-II-73

Solvent Solubility (µg/ml) Phosphate buffer (pH 7.4) 951.37 ± 41.38 Water (pH 5.2) $1,001.10 \pm 39.94$ 0.1 M HCl (pH 1.2) $5,370.70 \pm 195.26$ Medium-chain triglycerides 4,489.70 ±148.32 Soybean oil $3,055.05 \pm 137.42$ Castor oil $2,820.65 \pm 183.68$ Fish oil $2,395.07 \pm 331.00$ $131,047.81 \pm 6,902.35$ Isopropanol Methanol $> 1,469,735.25 \pm 93,891.20$

 $\log P = 2.09$


- The relatively good oil solubility of GL-II -73 in oils suggests that NEs act as promising carriers pHdependent solubility (increases with decreasing pH)
- ionizable functional groups
- multiple H-bond acceptors
- Solubility in organic solvents revealed that methanol is the best solvent for GL-II -73 (higher polarity index compared to isopropanol).

GL-II-73 (4R)-8-Ethynyl-6-(2-fluorophenyl)-N,N,4-trimethyl-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxamide

MATERIALS AND METHODS

Nanoemulsion preparation Adding aqueous to the oil phase Aqueous phase Oil phase medium chain glycerol polysorbate 80 triglycerides • **GL-II-73** (2mg/ml) soybean lecithin sodium oleate buthylhydroxytoluen Highly purified water **Emulsification** EmulsiFlex C3, **Preemulsification** Avestin 11000 rpm; 1 min 800 bar, 10 cycles 50 °C Physicochemical characterization Droplet size (Z-ave) Size distribution (PDI) Zeta potential (ZP) One month stability Drug content and **Encapsulation efficacy** pH and conductivity

RESULTS



The values are shown as mean \pm sd, n = 3

The values of physicochemical parameters: Z-ave, PDI, ZP, pH, conductivity, drug content, and encapsulation efficiency, measured both at baseline and after one month of storage, indicate suitability for parenteral administration. For the stabilization of the pH, further optimization is required.

REFERENCES

- 1. Bisso, S., Leroux, J.C., 2020. Int. J. Pharm., 578, 119098, do 10.1016/j.ijpharm.2020.119098
- 2. Ilić, T. et al. 2023. Pharmaceutics, 15(2), 443. doi: 10.3390/pharmaceutics15020443 3. Prevot, T.D. et al., 2019. Mol. Neuropsychiatry. 5(2), 84-97. doi: 10.1159/000496086

ACKNOWLEDGMENT

doi: This research was funded by the MESDT, Republic of Serbia through Grant Agreement with University of Belgrade-Faculty of Pharmacy No: 451-03-68/2022-14/200161 and supported by the Science Fund of the Republic of Serbia, GRANT No 7749108 - NanoCellEmoCog.